# Hermes-Epitek

> Hermes-Epitek is a VC fund backing Biopharma, Health Care and Real Estate. See 3 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Oct 2022
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.hermes.com.tw

Hermes-Epitek is a VC fund focused on Biopharma and Health Care. Hermes-Epitek provides semiconductor and optoelectronic manufacturing process equipment, technical services, and parts sales to help customers achieve production efficiency and assist original partners. The company aims to create a market share for equipment suppliers and implement localization to create cost-effective equipment solutions.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Real Estate | 1 | 33% |
| Smart Cities | 1 | 33% |
| Therapeutics | 1 | 33% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ochre Bio | Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M | Series A | Oct 10, 2022 |  |
| Ochre Bio | Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $9.6M | Seed | Jun 16, 2021 |  |
| Halio | Halio is transforming glass into responsive, intelligent, beautiful architectural elements that transition from clear to tinted to dark – automatically or on command. We're transforming architecture and design by offering a much more versatile architectural element for windows, walls, and skylights.We're transforming buildings andhomes to be more efficient, beautiful, and comfortable.Most importantly, we're transforming lives by giving people unprecedented comfort and control of their indoor environments and more connection to the outside world, while creating inspiring spaces for living and working.We’re doing it through technology. Halio technology is so advanced that we don’t call it electrochromic. Though it does tint when it receives an electrical charge, Halio tints up to 10x faster, it tints uniformly (no more iris or curtain effect), it looks like natural clear glass (no more honey hues), it tints to classic, neutral shades of gray (no more smurf blue), and finally, we give you unlimited tint level options. It's why we thought it needed to be called "smart-tinting glass."​And that’s just the glass itself. Our software and hardware controls are best-of-class – and they’re designed to work seamlessly with building management/automation systems.Beyond performance, our manufacturing techniques result in yields that match the flat panel display industry – and that means on-time deliveries, no matter where in the world your project is located. | $65M | Series C | Jan 31, 2017 |  |

3 of 3 investments shown.

## Co-investors
- [BACKED VC](https://shizune.co/investors/profile/backed-vc) — VC Fund, 2 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 2 deals together
- [Selvedge Venture](https://shizune.co/investors/profile/selvedge-venture) — VC Fund, 2 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Hermes-Epitek invest in?

Hermes-Epitek invests primarily in Biopharma, Health Care and Real Estate startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hermes-Epitek last invest?

The most recent investment recorded for Hermes-Epitek closed in Oct 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co